[Mood disorders].
Yamawaki
Narito
N
Takahashi
Terumichi
T
Imanaka
Akihiro
A
Kinoshita
Akiko
A
D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D001714:Bipolar Disorder / Q000175:diagnosis / Q000523:psychology / Q000628:therapy; D002668:Child Rearing / Q000523:psychology; D015928:Cognitive Behavioral Therapy; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007030:Hypothalamo-Hypophyseal System / Q000503:physiopathology; D007223:Infant; D018020:Lithium Compounds / Q000627:therapeutic use; D019964:Mood Disorders / Q000145:classification / Q000209:etiology / Q000523:psychology / Q000628:therapy; D010913:Pituitary-Adrenal System / Q000503:physiopathology; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D012931:Social Environment
D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D006854:Hydrocortisone; D018020:Lithium Compounds; D017367:Selective Serotonin Reuptake Inhibitors